Victoria Villaflor, MD joins UCI Health to share key insights from the 2025 ASCO Annual Meeting - Takeaways - MDSpire

Victoria Villaflor, MD joins UCI Health to share key insights from the 2025 ASCO Annual Meeting

Victoria Villaflor, MD, a recent addition to the UCI Health Chao Family Comprehensive Cancer Center faculty, highlights pivotal findings from ASCO 2025.

  • June 5, 2025

Share

  • 1

    Victoria Villaflor, MD, joined UCI Health to enhance cancer care through insights gained from the 2025 ASCO Annual Meeting.

  • 2

    The NIVOPOSTOP trial showed a 10% improvement in recurrence-free survival for high-risk head and neck cancer patients receiving nivolumab.

  • 3

    Immunotherapy is emerging as a practice-changing approach in head and neck oncology, particularly in postoperative settings.

  • 4

    The keynote 689 trial also indicated improved event-free survival with perioperative embrolizumab in head and neck cancer treatment.

  • 5

    Studies on cutaneous squamous cell carcinoma showed promising results for immunotherapy, with Cemiblimab demonstrating significant improvements.

Original Source(s)

Victoria Villaflor, MD joins UCI Health to share key insights from the 2025 ASCO Annual Meeting

  • June 5, 2025

Related Content

Synthetic short RNA in cancer

Bilateral renal metastasis following radical prostatectomy for prostate cancer: a case report

Validation of a cervical CDO1/CELF4 methylation test for endometrial cancer: a prospective paired-sample comparison with intrauterine specimen